Benchling, the R&D platform powering the biotech industry, has announced an expanded collaboration with Moderna. This collaboration, which initially supported Moderna's technical development teams, including analytical development, technical operations, process development, and formulations, will now extend across the company's research organization.

The expansion aims to integrate hundreds of Moderna's scientists into a unified, AI-ready research and development digital platform designed to accelerate discovery and innovation. Wade Davis, Senior Vice President, Digital at Moderna, stated that Moderna was founded on the principle that technology and science together drive breakthroughs in medicine and that AI is creating extraordinary opportunities in science. He emphasized that realizing AI's full potential requires new ways of working, and Benchling is addressing these industry-wide challenges, providing Moderna's scientists with a strong foundation for AI while empowering computational scientists and engineers.

Moderna and Benchling are focusing on three priorities for this digital transformation: consolidating systems to create a seamless experience for scientists, automating scientific workflows, and standardizing data into consistent, AI-ready formats. Sajith Wickramasekara, CEO and co-founder of Benchling, noted the constant pressure on R&D teams to move faster and work more efficiently and that AI and automation can unlock new levels of productivity, but only with the right infrastructure. He added that Moderna and Benchling are demonstrating the future of R&D: fully digital, deeply integrated, and built for intelligence and scale.

To innovate the infrastructure for AI in biotech, Moderna's research and technical development teams needed a flexible system capable of scaling with their pipeline. Benchling's digital platform meets these needs by balancing agility with out-of-the-box scientific workflows. Moderna's digital teams utilize Benchling's developer platform to build and deploy custom workflows, automate template generation, and integrate proprietary machine learning models. This shift reduces setup time for new workflows and enables high-throughput processing of experimental data, allowing digital teams to concentrate on innovation rather than maintaining systems.

As Benchling rolls out across the research organization, scientists can design experiments, track samples, and analyze results within a single system, eliminating the friction of disconnected tools. The platform also addresses the challenge of integrating both structured and unstructured data across diverse research environments, establishing a foundation for AI-driven analysis across therapeutic areas. Through this collaboration, Moderna and Benchling are redefining modern biotech research and setting a new standard for the digital infrastructure supporting AI-driven R&D.